Ikarian Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ikarian Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-170,000	Closed	-$28.9M	–	189
2025 Q4	$28.9M	Buy	170,000 +99,300	+140%	+$15.2M	2.26%	7
2025 Q3	$9.32M	Buy	+70,700	New	+$8.48M	0.94%	29
2024 Q1	–	Sell	-41,800	Closed	-$5.14M	–	162
2023 Q4	$5.14M	Buy	41,800 +41,382	+9,900%	+$5.16M	0.48%	58
2023 Q3	$5.41M	Buy	+418	New	+$55.7K	0.65%	47
2021 Q2	–	Sell	-100,000	Closed	-$16.4M	–	248
2021 Q1	$16.4M	Buy	+100,000	New	+$16.5M	0.55%	39

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Ikarian Capital's JAZZ Position: Q1 2026 in Review

Ikarian Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 92% in Q1 2026, selling an estimated $25.8M and leaving 12,460 shares worth $2.36M. The position accounts for 0.19% of the portfolio, ranked #94.

Ikarian Capital first reported a position in JAZZ in Q2 2025 and has held it in 4 quarters since. The position peaked at $27.3M in Q4 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Ikarian Capital held 12,460 shares of Jazz Pharmaceuticals worth $2.36M as of Q1 2026.
Ikarian Capital sold 147,907 Jazz Pharmaceuticals shares in Q1 2026, an estimated $25.8M.
Jazz Pharmaceuticals made up 0.19% of Ikarian Capital's portfolio in Q1 2026, its #94 holding.
Ikarian Capital first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
Ikarian Capital's Jazz Pharmaceuticals position peaked at $27.3M in Q4 2025.
571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.